Succinate links atrial dysfunction and cardioembolic stroke


To determine whether altered metabolic profiles represent a link between atrial dysfunction and cardioembolic (CE) stroke, and thus whether underlying dysfunctional atrial substrate may contribute to thromboembolism risk in CE stroke.


A total of 144 metabolites were measured using liquid chromatography–tandem mass spectrometry in plasma samples collected within 9 hours of stroke onset in 367 acute stroke patients. Stroke subtype was assigned using the Causative Classification of Stroke System, and CE stroke (n = 181) was compared to non-CE stroke (n = 186). Markers of left atrial dysfunction included abnormal atrial function (P-wave terminal force in lead V1, PTFV1 >4,000 μV·ms), left atrial enlargement on echocardiography, and frank atrial fibrillation on ECG. Stroke recurrence risk was assessed using CHADS2 and CHA2DS2-VASc scores. Associations between metabolites and CE stroke, atrial dysfunction, and stroke recurrence risk were evaluated using logistic regression models.


Three tricarboxylic acid metabolites—succinate (odds ratio [OR] 1.71, 95% confidence interval [CI] 1.36–2.15, p = 1.37 x 10–6), α-ketoglutarate (OR 1.62, 95% CI 1.29–2.04, p = 1.62 x 10–5), and malate (OR 1.58, 95% CI 1.26–1.97, p = 2.57 x 10–5)—were associated with CE stroke. Succinate (OR 1.36, 95% CI 1.31–1.98, p = 1.22 x 10–6), α-ketoglutarate (OR 2.14, 95% CI 1.60–2.87, p = 2.08 x 10–8), and malate (OR 2.02, 95% CI 1.53–2.66, p = 1.60 x 10–7) were among metabolites also associated with subclinical atrial dysfunction. Of these, succinate was also associated with left atrial enlargement (OR 1.54, 95% CI 1.23–1.94, p = 1.06 x 10–4) and stroke recurrence based on dichotomized CHADS2 (OR 2.63, 95% CI 1.68–4.13, p = 3.00 x 10–6) and CHA2DS2-VASc (OR 2.43, 95% CI 1.60–3.68, p = 4.25 x 10–6) scores.


Metabolite profiling identified changes in succinate associated with CE stroke, atrial dysfunction, and stroke recurrence, revealing a putative underlying link between CE stroke and energy metabolism.

Source link

Related posts

Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality


Fixel Center for Neurological Diseases at UF Health – Harnessing the Power of the Hub!


Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy